Genetic Influences on Response to Mood Stabilizers in Bipolar Disorder Current Status of Knowledge

被引:48
|
作者
Rybakowski, Janusz K. [1 ]
机构
[1] Poznan Univ Med Sci, Dept Adult Psychiat, PL-60572 Poznan, Poland
关键词
PROPHYLACTIC LITHIUM RESPONSE; SEROTONIN TRANSPORTER GENE; MITOCHONDRIAL-DNA POLYMORPHISMS; CLUSTER REGION GENE; LONG-TERM TREATMENT; POSSIBLE ASSOCIATION; MAINTENANCE TREATMENT; SARDINIAN PATIENTS; CANDIDATE GENES; NO ASSOCIATION;
D O I
10.1007/s40263-013-0040-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Mood stabilizers form a cornerstone in the long-term treatment of bipolar disorder. The first representative of their family was lithium, still considered a prototype drug for the prevention of manic and depressive recurrences in bipolar disorder. Along with carbamazepine and valproates, lithium belongs to the first generation of mood stabilizers, which appeared in psychiatric treatment in the 1960s. Atypical antipsychotics with mood-stabilizing properties and lamotrigine, which were introduced in the mid-1990s, form the second generation of such drugs. The response of patients with bipolar disorder to mood stabilizers has different levels of magnitude. About one-third of lithium-treated patients are excellent responders, showing total prevention of the episodes, and these patients are clinically characterized by an episodic clinical course, complete remission, a bipolar family history, low psychiatric co-morbidity and a hyperthymic temperament. It has been suggested that responders to carbamazepine or lamotrigine may differ clinically from responders to lithium. The main phenotype of the response to mood stabilizers is a degree of prevention against recurrences of manic and depressive episodes during long-term treatment. The most specific scale in this respect is the so-called Alda scale, where retrospective assessment of lithium response is scored on a 0-10 scale. The vast majority of data on genetic influences on the response to mood stabilizers has been gathered in relation to lithium. The studies on the mechanisms of action of lithium and on the neurobiology of bipolar disorder have led to the identification of a number of candidate genes. The genes studied for their association with lithium response have been those connected with neurotransmitters (serotonin, dopamine and glutamate), second messengers (phosphatidyl inositol [PI], cyclic adenosine-monophosphate [cAMP] and protein kinase C [PKC] pathways), substances involved in neuroprotection (brain-derived neurotrophic factor [BDNF] and glycogen synthase kinase 3-beta [GSK-3 beta]) and a number of other miscellaneous genes. There are no published pharmacogenomic studies of mood stabilizers other than lithium, except for one study of the X-box binding protein 1 (XBP1) gene in relation to the efficacy of valproate. In recent years, a number of genome-wide association studies (GWAS) in bipolar disorders have been performed and some of those have also focused on lithium response. They suggest roles for the glutamatergic receptor AMPA (GRIA2) gene and the amiloride-sensitive cation channel 1 neuronal (ACCN1) gene in long-term lithium response. A promise for better elucidating the genetics of lithium response has been created by the formation of the Consortium on Lithium Genetics (ConLiGen) to establish the largest sample, to date, for the GWAS of lithium response in bipolar disorder. The sample currently comprises more than 1,200 patients, characterized by their response to lithium treatment according to the Alda scale. Preliminary results from this international study suggest a possible involvement of the sodium bicarbonate transporter (SLC4A10) gene in lithium response. It is concluded that the pharmacogenetics of response to mood stabilizers has recently become a growing field of research, especially so far as the pharmacogenetics of the response to lithium is concerned. Clearly, the ConLiGen project is a highly significant step in this research. Although the results of pharmacogenetic studies are of significant scientific value, their possible practical implications are yet to be seen.
引用
收藏
页码:165 / 173
页数:9
相关论文
共 50 条
  • [21] Trajectories of adherence to mood stabilizers in patients with bipolar disorder
    M. Bauer
    T. Glenn
    M. Alda
    R. Bauer
    P. Grof
    W. Marsh
    S. Monteith
    R. Munoz
    N. Rasgon
    K. Sagduyu
    P. C. Whybrow
    International Journal of Bipolar Disorders, 7
  • [22] The current status and prospects for genetic studies of bipolar disorder
    DePaulo, JR
    Phillips, AE
    Potash, JA
    McInnis, MG
    McMahon, FJ
    CLINICAL NEUROSCIENCE RESEARCH, 2001, 1 (1-2) : 153 - 157
  • [23] Advances in Mood Disorder Pharmacotherapy: Evaluating New Antipsychotics and Mood Stabilizers for Bipolar Disorder and Schizophrenia
    Kowalczyk, Emilia
    Koziej, Sylwia
    Soroka, Ewelina
    MEDICAL SCIENCE MONITOR, 2024, 30
  • [24] Predictors of response for mood stabilizers in bipolar affective disorders
    Walden, J
    Normann, C
    Langosch, J
    Grunze, H
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 1999, 67 (02) : 75 - 80
  • [25] Use of mood stabilizers by hospitalized geriatric patients with bipolar disorder
    Sanderson, DR
    PSYCHIATRIC SERVICES, 1998, 49 (09) : 1145 - 1147
  • [26] Efficacy of olanzapine combined with mood stabilizers in the treatment of bipolar disorder
    Tohen, KF
    Tohen, M
    Timpe, TM
    Risser, R
    Chengappa, KR
    Suppes, TR
    Feldman, PD
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 248 - 248
  • [27] A retrospective survey on medication of mood stabilizers against bipolar disorder
    Tomioka, Hiroi
    Nakagome, Kazuyuki
    Matsumaru, Kentaro
    Muramatsu, Dai
    Oawshi, Toshimi
    Nakamura, Kei
    Kamijima, Kunitoshi
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2006, 21 (04) : A27 - A27
  • [28] Mood stabilizers in hospitalized children with bipolar disorder: A retrospective review
    Davanzo, P
    Gunderson, B
    Belin, T
    Mintz, J
    Pataki, C
    Ott, D
    Emley-Akanno, C
    Montazeri, N
    Oppenheimer, J
    Strober, M
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2003, 57 (05) : 504 - 510
  • [29] Mood stabilizers in the treatment of juvenile bipolar disorder - Advances and controversies
    Davanzo, PA
    McCracken, JT
    CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA, 2000, 9 (01) : 159 - +
  • [30] DNA methylation signatures of mood stabilizers and antipsychotics in bipolar disorder
    Houtepen, Lotte C.
    van Bergen, Annet H.
    Vinkers, Christiaan H.
    Boks, Marco P. M.
    EPIGENOMICS, 2016, 8 (02) : 197 - 208